Muhammad Sanusi, Sani Mahmoud Umar, Okeahialam Basil N
Department of Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.
Niger Med J. 2013 May;54(3):185-90. doi: 10.4103/0300-1652.114591.
Highly active antiretroviral therapy (HAART) has become more accessible to Human immunodeficiency virus infection/Acquired Immunodeficiency Syndrome (HIV/AIDS) patients worldwide. There is growing concern that the metabolic complications associated with HIV and HAART may increase cardiovascular risk and lead to cardiovascular diseases. We, therefore, set out to describe the cardiovascular risk profile of HIV/AIDS patients receiving HAART at a health facility in northern part of Nigeria.
This cross-sectional study was conducted at the Aminu Kano Teaching Hospital, Kano, Nigeria. Consenting patients, who had been receiving HAART, were compared with age and sex matched HAART-naive subjects. Questionnaire interview, electrocardiography, anthropometric and blood pressure measurements were conducted under standard conditions. Blood samples were obtained for the determination of plasma glucose, uric acid and lipid levels.
Two hundred subjects were studied, 100 were on HAART (group 1) and the other 100 (group 2) were HAART-naive. Subjects' mean age for all the participants was 32.5 (7.6) years. The prevalence of hypertension was 17% in group 1 and 2% in group 2 (P < 0.001). Similarly, 11% and 21% of group 1 subjects were obese or had metabolic syndrome compared with 2% and 9% of group 2 patients (P < 0.05 for both).
HAART treatment was associated with significantly higher prevalences of hypertension, obesity and metabolic syndrome.
高效抗逆转录病毒疗法（HAART）在全球范围内已使更多的人类免疫缺陷病毒感染/获得性免疫缺陷综合征（HIV/AIDS）患者能够接受治疗。人们越来越担心与HIV和HAART相关的代谢并发症可能会增加心血管疾病风险并导致心血管疾病。因此，我们着手描述在尼日利亚北部一家医疗机构接受HAART治疗的HIV/AIDS患者的心血管疾病风险状况。
这项横断面研究在尼日利亚卡诺的阿米努·卡诺教学医院进行。将同意参与研究的正在接受HAART治疗的患者与年龄和性别匹配的未接受过HAART治疗的受试者进行比较。在标准条件下进行问卷调查、心电图检查、人体测量和血压测量。采集血样以测定血浆葡萄糖、尿酸和血脂水平。
共研究了200名受试者，其中100名正在接受HAART治疗（第1组），另外100名（第2组）未接受过HAART治疗。所有参与者的平均年龄为32.5（7.6）岁。第1组高血压患病率为17%，第2组为2%（P<0.001）。同样，第1组分别有11%和21%的受试者肥胖或患有代谢综合征，而第2组患者的这一比例分别为2%和9%（两者P均<0.05）。
HAART治疗与高血压、肥胖和代谢综合征的显著更高患病率相关。
